Genetic variation in GLP-1 receptor pathways, FTO signaling, and GIPR expression can influence how individuals respond to semaglutide or tirzepatide, though individual response remains multifactorial
No large-scale clinical evidence supports twice-weekly dosing, which is why it remains off-label and not recommended
The approval was based on the OASIS clinical trial programme and the SELECT cardiovascular outcomes trial, with the OASIS 4 study showing a mean weight loss of 16.6% at 64 weeks in adults with obesity or overweight, among participants who adhered to treatment
A limitation of the present analysis is that we cannot exclude the possibility that other demographic factors that we did not evaluate were influential in the target patient population
Because Wegovy can cost over $1,000 per month without prescription drug coverage, its important to check plan details
From Marina del Rey to Beverly Hills, clients are achieving meaningful weight loss results but many are discovering that the skin doesnt always keep pace with the bodys transformation